Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Payables (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Payables for 3 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • Quarterly Payables rose 20.36% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.2 million through Dec 2025, up 20.36% year-over-year, with the annual reading at $15.2 million for FY2025, 20.36% up from the prior year.
  • Payables for Q4 2025 was $15.2 million at Nuvation Bio, down from $21.0 million in the prior quarter.
  • The five-year high for Payables was $28.0 million in Q2 2025, with the low at $2.2 million in Q4 2023.
  • Average Payables over 3 years is $11.9 million, with a median of $13.9 million recorded in 2024.
  • Peak annual rise in Payables hit 776.78% in 2024, while the deepest fall reached 17.28% in 2024.
  • Over 3 years, Payables stood at $2.2 million in 2023, then surged by 471.8% to $12.6 million in 2024, then rose by 20.36% to $15.2 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $15.2 million, $21.0 million, and $28.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.